This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A short examination of how index fund return variance evolves across decades and what it means for risk budgets.
25,652 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
NexaTech Holdings, a $40 billion market-cap company, raised its revenue guidance on stronger-than-expected demand, si...
Investors are turning to ASML to gauge the health of the global chip cycle. This article breaks down the factors like...
A stock can crater 97% and still look tempting for income investors. This guide walks you through the due diligence, ...
Intel faces execution and competition risks, but a potential anchor from Apple and sustained AI demand could keep its...
Nvidia is moving beyond chips into AI agents, changing how businesses deploy AI and how investors should value the co...
Big tech is pouring hundreds of billions into AI infrastructure. This creates opportunities for selective stocks. Lea...
A new analyst survey shows overwhelming Buy ratings for Amazon, with no Sell calls. The result comes as AWS accelerat...
CoreWeave's stock has fallen sharply in May as costs rise and guidance disappoints. This guide breaks down the reason...
Nvidia just delivered another earnings beat and a bold $80 billion buyback. As AI infrastructure spending accelerates...
Gaotu's Q1 2026 earnings reveal clues about growth, profitability, and execution in a competitive online education ma...
June data show existing home sales beat forecasts, signaling ongoing demand strength in 2026. The numbers point to st...